[Botulinum toxin in tension-type headache].
Botulinum toxin has meanwhile been approved for a number of indications. It is also gaining acceptance in other indications with a major focus on pain. The most common type of headache is tension-type headache (TTH) the pathogenesis of which has not yet been unfolded. As it looks there are vascular, myofascial and supraspinal factors intertwined. It is felt that headache is triggered by myofascial stimuli. The application of botulinum toxin is an intelligent alternative since the favorable effect of pharmacologic and other therapies is limited. Application of BTX should be considered when the pericranial muscles are involved. One of the effects produced lies in the reduction of muscular stress, muscular ischemia and muscle tone. We still don't know whether additional mechanisms such as retrograde uptake and direct antiinflammatory potential are involved. Current data permit the conclusion that headaches are decreased in their frequency and distinctiveness. Significant untoward effects are not to be expected. Neither the ideal dose nor the optimum selection of injection sites have been established as yet, an individual injection scheme is apparently most promising. Injection of the trigger points seems to make sense.
Jost
W H
WH
Fachbereich Neurologie der Deutschen Klinik für Diagnostik, Wiesbaden. jost.neuro@dkd-wiesbaden.de
D001905:Botulinum Toxins / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D006801:Humans; D007273:Injections, Intramuscular; D018781:Tension-Type Headache / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology
D001905:Botulinum Toxins